Skip to main content
. 2022 Sep 6;14:17588359221113693. doi: 10.1177/17588359221113693

Table 3.

(A) Target therapy DIPG patients: first-line and relapse treatment details. (B) Control group DIPG patients: first-line and relapse treatment details.

(A)

Patients Age at diagnosis (years) Gender Backbone treatment Target treatment Target finding Other treatment Sides effects OS (months)
1 11.93 M RTX + temozolomide Everolimus m/pmTOR IHC expression bevacizumab
N/V
re-irradiation
Aftosis stomatitis grade II 26.57
2 5.06 F RTX + N/V Palovarotene ACVR1 mutation Bevacizumab
temozolomide
re-irradiation
No 14.37
3 8.77 F RTX + N/V Pazopanib PDGFRA Bevacizumab
temozolomide
re-irradiation
Headache grade II 18.00
4 5.04 F RTX + N/V Everolimus m/pmTOR IHC expression Bevacizumab
temozolomide
No 13.97
5 5.65 F RTX + N/V everolimus m/pmTOR IHC expression No (refused) No 12.07
6 5.98 M RTX + N/V everolimus m/pmTOR IHC expression Bevacizumab
temozolomide
re-irradiation
No 20.47
7 6.61 M RTX + N/V everolimus and vemurafenib m/pmTOR and BRAF IHC expression Bevacizumab
temozolomide
re-irradiation
Aftosis stomatitis grade II 27.50
8 7.79 F RTX + N/V everolimus m/pmTOR IHC expression Bevacizumab
temozolomide
re-irradiation
No 32.20
9 6.01 F RTX + N/V palovarotene ACVR1 mutation Bevacizumab
temozolomide
re-irradiation
Grade III skin toxicity 20.43